Class summary at a glance.

Every drug in the Gonadotropin Releasing Hormone Receptor Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $308.8Mcombined across class
Total Rx claims: 68K32K unique beneficiaries
Generic mfrs (active): 8across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Leuprolide

Brand: CAMCEVI · 68K Part D claims (CY24) · 32K beneficiaries · First FDA approval: 1989-01-26

8 generic mfrs 3079 plans require PA

Low NADAC$220.12

→

Avg plan cost$1593.01

Part D spend $308.8M 7× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.